In the European pharmaceutical industry, there were 103 M&A deals announced in Q2 2023, worth a total value of $9.6bn, according to GlobalData’s Deals Database. The $6.1bn acquisition of dechra pharmaceuticals by freya bidco was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, M&A activity in Europe increased by 104% in Q2 2023 compared with the previous quarter’s total of $4.7bn and rose by 439% as compared to Q2 2022. Related deal volume increased by 37% in Q2 2023 versus the previous quarter and was 102% higher than in Q2 2022.
The top-ranked financial advisors supporting these M&A deals in Europe in Q2 2023 were KPMG International Coop; Bank of America; Clearwater International with 4, 3, 3 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Europe Q2 2023 were CMS Legal Services EEIG; Baker & McKenzie; White & Case with 10, 5, 5 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.